ECQ Stock Overview
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
PharmAust Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.046 |
| 52 Week High | AU$0.066 |
| 52 Week Low | AU$0.032 |
| Beta | 0.59 |
| 1 Month Change | 22.67% |
| 3 Month Change | 10.84% |
| 1 Year Change | -26.98% |
| 3 Year Change | -5.15% |
| 5 Year Change | 27.78% |
| Change since IPO | -95.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ECQ | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 31.4% | 6.6% | 4.3% |
| 1Y | -27.0% | -2.4% | -16.4% |
Return vs Industry: ECQ underperformed the German Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: ECQ underperformed the German Market which returned -16.4% over the past year.
Price Volatility
| ECQ volatility | |
|---|---|
| ECQ Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ECQ is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ECQ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Roger Aston | https://www.pharmaust.com |
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer.
PharmAust Limited Fundamentals Summary
| ECQ fundamental statistics | |
|---|---|
| Market Cap | €16.84m |
| Earnings (TTM) | -€1.10m |
| Revenue (TTM) | €2.89m |
5.8x
P/S Ratio-15.4x
P/E RatioIs ECQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECQ income statement (TTM) | |
|---|---|
| Revenue | AU$4.51m |
| Cost of Revenue | AU$314.34k |
| Gross Profit | AU$4.20m |
| Other Expenses | AU$5.90m |
| Earnings | -AU$1.71m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0053 |
| Gross Margin | 93.03% |
| Net Profit Margin | -37.87% |
| Debt/Equity Ratio | 2.7% |
How did ECQ perform over the long term?
See historical performance and comparison